

AMENDMENTS TO THE CLAIMS

Please enter amendments as shown below. Insertions and deletions are indicated with underlining and strikethrough or double-brackets, respectively.

1-99. (Canceled)

100. (Currently amended) An oligonucleotide having the following structure:
5' T*C_G*T*C_G*T*T*T*T*G*A*C_G*T*T*T*T*G*T*C_G*T*T 3' (SEQ ID NO: 313),
wherein * refers to the presence of a stabilized internucleotide linkage, and wherein _ refers to the presence of a phosphodiester internucleotide linkage and wherein the oligonucleotide has a length of [[16]] 24-40 nucleotides.

101. (Currently amended) The oligonucleotide of claim 100, wherein the oligonucleotide consists essentially of 5' T*C_G*T*C_G*T*T*T*T*G*A*C_G*T*T*T*T*G*T*C_G*T*T 3' (SEQ ID NO: 313).

102. (Currently amended) The oligonucleotide of claim 100, wherein the oligonucleotide consists of 5' T*C_G*T*C_G*T*T*T*T*G*A*C_G*T*T*T*T*G*T*C_G*T*T 3' (SEQ ID NO: 313).

103. (Canceled)

104. (Previously Presented) The oligonucleotide of claim 100, wherein the stabilized internucleotide linkage is a phosphorothioate internucleotide linkage.

105. (Previously Presented) An oligonucleotide having the following structure: 5' T*C_G*T*C_G*T*T*T*T*G*A*C_G*T*T*T*T*G*T*C_G*T*T 3' (SEQ ID NO: 313) wherein each * refers to a phosphorothioate internucleotide linkage and each _ refers to a phosphodiester internucleotide linkage, and wherein the oligonucleotide is 24 nucleotides in length.

106. (Previously Presented) A pharmaceutical composition comprising an oligonucleotide as defined in claim 100 and a pharmaceutically acceptable carrier.

107. (Previously Presented) A pharmaceutical composition comprising an oligonucleotide as defined in claim 105 and a pharmaceutically acceptable carrier.